Recombinant HRP Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab208430)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [EPR9515(2)] to MLKL (phospho S345)
- Suitable for: Dot blot, WB
- Reacts with: Mouse
- Conjugation: HRP
Related conjugates and formulations
Overview
-
Product name
HRP Anti-MLKL (phospho S345) antibody [EPR9515(2)]
See all MLKL primary antibodies -
Description
HRP Rabbit monoclonal [EPR9515(2)] to MLKL (phospho S345) -
Host species
Rabbit -
Conjugation
HRP -
Specificity
MLKL pS345 is a trigger for necroptosis. It is only detectable in infection/cellular damaged (PMID:29229989) or aging tissue (PMID: 28807105) but not in normal tissues. -
Tested applications
Suitable for: Dot blot, WBmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- L-929 cells.
-
General notes
This antibody was developed through collaboration with the lab of Xiaodong Wang at the National Institute of Biological Sciences, Beijing.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 1% BSA, 30% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR9515(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab208430 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Dot blot |
1/1000.
|
|
WB |
1/4500. Predicted molecular weight: 54 kDa.
|
Notes |
---|
Dot blot
1/1000. |
WB
1/4500. Predicted molecular weight: 54 kDa. |
Target
-
Sequence similarities
Belongs to the protein kinase superfamily.
Contains 1 protein kinase domain. -
Domain
The protein kinase domain is predicted to be catalytically inactive. - Information by UniProt
-
Database links
- Entrez Gene: 74568 Mouse
- SwissProt: Q9D2Y4 Mouse
- Unigene: 207971 Mouse
-
Alternative names
- 9130019I15Rik antibody
- FLJ34389 antibody
- hMLKL antibody
see all
Images
-
All lanes : HRP Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab208430) at 1/4500 dilution
Lane 1 : Untreated L-929 (Mouse connective tissue fibroblast cell line) whole cell lysates
Lane 2 : L-929 (Mouse connective tissue fibroblast cell line) treated with 20 ng/ml TNF alpha,100nM Smac mimetic , and 20mM z-VAD for 8 hours whole cell lysates
Lane 3 : L-929 (Mouse connective tissue fibroblast cell line) treated with 20 ng/ml TNF alpha, 100nM Smac mimetic , and 20mM z-VAD for 8 hours whole cell lysates. Then the membrane was incubated with Alkaline phosphatase.
Lysates/proteins at 15 µg per lane.
Predicted band size: 54 kDa
Observed band size: 54 kDa
Exposure time: 1 minuteBlocking and diluting buffer: 5% NFDM/TBST.
-
Dot Blot analysis of
Lane 1: MLKL (phospho S345) phospho peptide and
Lane 2: MLKL Non-phospho peptide labeling MLKL (phospho S345)
with ab208430 at 1/1000 dilution. 5% NFDM/TBST was used as the diluting and blocking buffer. Exposure time: 3 minutes.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab208430 has not yet been referenced specifically in any publications.